Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 12 weight-loss maintenance study of once-weekly subcutaneous zenagamtide in adults with obesity
2025-523804-62-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 12
01
Overview
Phase 3, randomised trial in obesity comparing Zenagamtide once weekly with Placebo once weekly (2 arms). Primary endpoint: Relative change in body weight. Planned start Apr 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on 2025-523804-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523804-62-00.